Similarly, Fu et al. found that BIRC2 downregulates MHC-I expression by promoting ubiquitin-mediated degradation of NIK in hepatocellular carcinoma (HCC), and its inhibition in combination with ICIs enhances antitumor efficacy[75]. Here, BIRC2 is linked to hepatocellular carcinoma.